A Phase IV, Open-Label, Multicenter Study of the Efficacy and Safety of Quadruple Combination Antiretroviral Therapy With Combivir (Lamivudine 150mg/Zidovudine 300mg) BID, Ziagen (Abacavir) 300mg BID, and Sustiva (Efavirenz) 600mg QD for 24 Weeks, Followed by the Triple Nucleoside Combination Tablet (Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg) BID Plus Sustiva (Efavirenz) 600mg QD for 24 Weeks in HIV-Infected Adults

NCT00004585 Phase 4 COMPLETED

The purpose of this study is to see if a certain combination of anti-HIV drugs is safe and effective in HIV-infected patients. The drug combination includes a tablet containing lamivudine and zidovudine (called Combivir) plus abacavir plus efavirenz.

Details

Lead sponsor	Glaxo Wellcome
Phase	Phase 4
Status	COMPLETED
Enrolment	40
Start date	1999-10

Conditions

• HIV Infections

Interventions

• Abacavir sulfate, Lamivudine and Zidovudine
• Lamivudine/Zidovudine
• Abacavir sulfate
• Efavirenz

Countries

United States